Markers of Oxidative Stress in Inflammatory Bowel Diseases: Risk Factors and Implications for a Dietetic Approach (OxIBDiet)

November 28, 2023 updated by: Carlo Catassi, M.D., Università Politecnica delle Marche

Markers of Oxidative Stress in Inflammatory Bowel Disease in Children and Adults: Risk Factors and Implications for a Dietetic Approach

Inflammatory bowel disease (IBD), including Crohn's disease (CD), Ulcerative Colitis (UC) and IBD-unclassified (IBD-U) is a chronic inflammatory intestinal disorders that affect both children and adults. Patients with IBD can present with severe gastrointestinal symptoms, require frequent hospitalizations, expensive medical treatments and can develop invalidating complications requiring surgery. The incidence of IBD is increasing worldwide. The pathogenesis is multifactorial with immunological, environmental and genetic factors contributing to the disease. There is evidence that oxidative stress (OS) imbalance is involved in IBD onset and evolution, although the exact contribution to the pathogenes is unclear. An antioxidant dietetic approach is promising as an adjunctive treatment of IBD. The main aims of this project are to characterize the OS imbalance in IBD in relation to disease's features and to genetic factors and to evaluate the efficacy of an antioxidant dietetic treatment

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

IBD is a complex disorder that is thought to be the result of an aberrant immune response to commensal bacteria in a genetically susceptible host. The chronic inflammation along the gastrointestinal tract that characterizes IBD results from an imbalance of effector lymphocytes and pro-inflammatory cytokines. Some of the cytokines, as well as the triggered leukocytes and activated macrophages, can produce large amounts of reactive oxygen species (ROS) thus predisposing to oxidative stress disturbances. Many of the clinical and pathophysiological features of IBD, particularly tissue injury (mucosal erosions) and fibrosis have been associated to redox imbalance due to continuous ROS production and a net decrease of antioxidant molecules. Although uncontrolled oxidative stress is destructive in inflammatory conditions, the body's antioxidant defenses can counteract the effects caused by excess of ROS. Antioxidants are protective molecules/compounds toward pro-oxidant molecules. They can be endogenous or/and come from the diet. Endogenous compounds include intracellular enzymatic antioxidants such as superoxide dismutases (SODs), glutathione peroxidase (GPX), and catalase (CAT), intracellular nonenzymatic antioxidant such as glutathione (GSH) and extracellular antioxidants such as vitamins (Vit. A-C-E-B group). GSH is considered the major non-protein low molecular weight defender against oxidative (or redox) stress and the most important cellular thiol buffer. Moreover it acts as cofactor for the antioxidant enzymes GPxs and GST. GSH has been used as a biomarker for inflammation and several studies showed reduced levels of GSH in inflammatory conditions. Experimental colitis models showed decreased GSH levels that can be restored to a normal level by antioxidants supplementation. Also antioxidant enzymes as SODs, CAT and GPxs were found dysregulated in IBD condition. The differences in the regulation of expression of SOD, CAT and GPxs may not only reflect their importance in physiology, but may be also insufficient in removal of ROS under inflammatory conditions such as IBD.

Recently an association between SOD1, CAT and GSHPX1 polymorphisms and the risk of inflammatory bowel disease in the Polish population has been described. Kosaka et al. found a correlation between age of onset and severity of IBD with polymorphisms in SOD2 manganese superoxide dismutase and NAD(P)H quinone oxidoreductase. In this respect, IBD disease can be regarded as multifactorial disease. There are several lines of evidence to suggest that diet is a key player in the onset, perpetuation and management of IBD. The most important evidence linking diet to IBD comes from exclusive enteral nutrition (EEN) that is the primary induction treatment of active paediatric Crohn Disease (CD). Epidemiological evidence associates certain dietary nutrients and components to the increased risk of IBD. There is emerging evidence that some diets, including the Specific Carbohydrate Diet (SCD) and the CD Exclusion Diet (CDED) could treat or prevent subsequent disease flare. Data previously presented induce to the hypothesis that an antioxidant dietetic approach, could have a role in the treatment of IBD. Dietary antioxidants may include ascorbic acid, vitamin E, glutathione, methionine, carotenoids, polyphenolic compounds, selenium and vitamin A. Clinical experience evaluating antioxidant dietetic approach in IBD patients is limited to few studies, mostly investigating the effects of single antioxidants in small number of patients. So far pediatric data regarding the oxidative status in children with IBD have rarely been reported. Collecting data in IBD children and comparing these with adults data, particularly in subjects at diagnosis, would give the unique opportunity to evaluate the role of oxidative stress in IBD pathogenesis. OxIBDiet working hypothesis is that oxidative stress imbalance is a key feature of IBD and the persistence of such imbalance is likely to contribute to the development of complications and more broadly to the evolution of the disease. A comparison between oxidative stress imbalance in children and adults with IBD and controls will address the question whether the stress imbalance is a consequence or a primary event in the inflammatory burden of IBD. Addressing these pathways and targeting the oxidative damage can have potential implications in IBD monitoring and treatment.

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Italy
      • Ancona, Italy, 60123
        • Recruiting
        • SOD Clinica Pediatrica, Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona
        • Contact:
        • Contact:
      • Ancona, Italy, 60126
        • Recruiting
        • SOD Clinica di Gastroenterologia, Epatologia ed Endoscopia Digestiva, Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years to 80 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

- Diagnosis of IBD

Exclusion Criteria:

  • permanent stoma
  • cancer
  • cardiovascular disease
  • ischemic disease
  • Alzheimer's disease
  • type 2 diabetes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Antioxidant diet
Group Antioxidant diet will receive 8 weeks of antioxidant dietary treatment
Dietary supplement: Antioxidant diet
The "antioxidant diet" will include the principal antioxidant molecules/nutrients previously shown to be beneficial in IBD: Flavonoids, particularly resveratrol and curcumin; Olive oil; Glutathione, Vitamins A, C, E; Carotenoids; Selenium and Omega 3 Fatty Acids (PUFAs). The daily amount of these substances will be calculated following the published evidence, whether these amounts will not be achievable by a standard diet, a supplementary formulation will be proposed.
Active Comparator: Normal diet
Group Normal diet will continue a normal dietetic scheme (corresponding to a isocaloric, normolipidic diet for age and sex).
Dietary supplement: Normal dietetic scheme
Isocaloric, normolipidic diet for age and sex

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood levels of ROS and glutathione in patients with IBD and controls
Time Frame: Baseline
Blood levels of ROS will be determined by cytofluorimetry, blood levels of glutathione by spectrofluorimetry
Baseline
Total antioxidant capacity (Trolox equivalent and ferrous equivalent) in patients with IBD and controls
Time Frame: Baseline
Trolox equivalent will be assessed by antioxidant assay Kit, ferrous equivalent instead wille require a manual assessment.
Baseline
Antioxidant enzymes pattern (GST, SOD, GPxs, GR enzyme levels, activity and transcripts) in patients with IBD and controls
Time Frame: Baseline
Spectrophotometer will be used to assess enzyme levels and activity, cDNA kit to determine enzyme transcripts.
Baseline
Plasma hydroperoxides and thiobarbituric acid reactive species in patients with IBD and controls
Time Frame: Baseline
Plasma hydroperoxides will be detected by LPO ELISA kit, thiobarbituric acid reactive species by TBARS assay kit.
Baseline
Urine oxidized guanines (8-OHdG, 8-OHG e guanosine) levels in patients with IBD and controls
Time Frame: Baseline
DNA/RNA oxydate damage kit will be used to study urine oxidized guanines levels.
Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Polymorphisms of genes implicated in oxidative stress defense (SOD1, SOD2, SOD3; GPX1, GPX2, GPX3; GPX4; GPX5; GSTA1; GSTA2; GSTM1; GSTM2; GSTM3; GSTP1; GSTO1; NQ01 NQ02; NOX1; NOX3; NOX4 and NOX5 genes) in patients with IBD and controls
Time Frame: Baseline
Genetic polymorphisms will be studied by next generation sequencing
Baseline

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood levels of ROS and glutathione in patients with IBD after a specific antioxidant dietary treatment
Time Frame: 12 weeks
Blood levels of ROS will be determined by cytofluorimetry, blood levels of glutathione by spectrofluorimetry at baseline and after 12 weeks of dietary treatment.
12 weeks
Total antioxidant capacity (Trolox equivalent and ferrous equivalent) in patients with IBD after a specific antioxidant dietary treatment
Time Frame: 12 weeks
Trolox equivalent will be assessed by antioxidant assay Kit, ferrous equivalent instead wille require a manual assessment at baseline and after 12 weeks of dietary treatment.
12 weeks
Antioxidant enzymes pattern (GST, SOD, GPxs, GR enzyme levels, activity and transcripts) in patients with IBD after a specific antioxidant dietary treatment
Time Frame: 12 weeks
Spectrophotometer will be used to assess enzyme levels and activity, cDNA kit to determine enzyme transcripts at baseline and after 12 weeks of dietary treatment
12 weeks
Plasma hydroperoxides and thiobarbituric acid reactive species in patients with IBD after a specific antioxidant dietary treatment
Time Frame: 12 weeks
Plasma hydroperoxides will be detected by LPO ELISA kit, thiobarbituric acid reactive species by TBARS assay kit at baseline and after 12 weeks of dietary treatment.
12 weeks
Urine oxidized guanines (8-OHdG, 8-OHG e guanosine) levels in patients with IBD after a specific antioxidant dietary treatment
Time Frame: 12 weeks
DNA/RNA oxydate damage kit will be used to study urine oxidized guanines levels at baseline and after 12 weeks of dietary treatment
12 weeks
PUCAI in pediatric patients with RCU after a specific antioxidant dietary treatment
Time Frame: 12 weeks
PUCAI score will be recorded at baseline and after 12 weeks of dietary treatment
12 weeks
PCDAI in pediatric patients with CD after a specific antioxidant dietary treatment
Time Frame: 12 weeks
PCDAI score will be recorded at baseline and after 12 weeks of dietary treatment
12 weeks
Phisician Global Assessment (PGA) score in patients with IBD after a specific antioxidant dietary treatment
Time Frame: 12 weeks
PGA score will be recorded at baseline and after 12 weeks of dietary treatment
12 weeks
Calprotectin levels in patients with IBD after a specific antioxidant dietary treatment
Time Frame: 12 weeks
Calprotectin levels will be analyzed in stool samples collected at baseline and after 12 weeks of dietary treatment
12 weeks
Harvey-Bradshaw score in adult patients with CD after a specific antioxidant dietary treatment
Time Frame: 12 weeks
Harvey-Bradshaw score will be recorded at baseline and after 12 weeks of dietary treatment
12 weeks
Mayo score in adult patients with RCU after a specific antioxidant dietary treatment
Time Frame: 12 weeks
Mayo score will be recorded at baseline and after 12 weeks of dietary treatment
12 weeks
PedQoL score in pediatric patients with IBD after a specific antioxidant dietary treatment
Time Frame: 12 weeks
PedQoL score will be recorded at baseline and after 12 weeks of dietary treatment
12 weeks
QoL score in adult patients with IBD after a specific antioxidant dietary treatment
Time Frame: 12 weeks
QoL score will be recorded at baseline and after 12 weeks of dietary treatment
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Università Politecnica delle Marche

Investigators

  • Principal Investigator: Carlo Catassi, Professor, Università Politecnica delle Marche

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 15, 2019

Primary Completion (Estimated)

December 8, 2023

Study Completion (Estimated)

December 8, 2023

Study Registration Dates

First Submitted

July 27, 2020

First Submitted That Met QC Criteria

August 11, 2020

First Posted (Actual)

August 14, 2020

Study Record Updates

Last Update Posted (Actual)

November 29, 2023

Last Update Submitted That Met QC Criteria

November 28, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • OxIBDiet-2020

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Individual participant data that underlie the results reported in this article after deidentification will be shared

IPD Sharing Time Frame

Beginning 9 months and ending 36 months following article publication

IPD Sharing Access Criteria

Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Inflammatory Bowel Diseases

Clinical Trials on Antioxidant diet

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe